PIK3CB and cancer: The effects of PI3K inhibition on T-cell infiltration and activation in tumors, thus leading to improved T-cell mediated cytotoxicity with ICI, has been well characterized in multiple pre-clinical models of immunogenic and immune-restricted cancers, however the mechanism of such effects depends which PI3K isoforms are targeted (108, 109).